Undisclosed antiretroviral drug use in Botswana: implication for national estimates
Sikhulile Moyo, Simani Gaseitsiwe, Kathleen M Powis, Molly Pretorius Holme, Terence Mohammed, Melissa Zahralban-Steele, Etienne K Yankinde, Comfort Maphorisa, William Abrams, Refeletswe Lebelonyane, Kutlo Manyake, Tumalano Sekoto, Mompati Mmalane, Tendani Gaolathe, Kathleen E Wirth, Joseph Makhema, Shahin Lockman, William Clarke, Max Essex, Vlad Novitsky, Sikhulile Moyo, Simani Gaseitsiwe, Kathleen M Powis, Molly Pretorius Holme, Terence Mohammed, Melissa Zahralban-Steele, Etienne K Yankinde, Comfort Maphorisa, William Abrams, Refeletswe Lebelonyane, Kutlo Manyake, Tumalano Sekoto, Mompati Mmalane, Tendani Gaolathe, Kathleen E Wirth, Joseph Makhema, Shahin Lockman, William Clarke, Max Essex, Vlad Novitsky
Abstract
: Among 3596 HIV-positive participants enrolled in the Botswana Combination Prevention Project who self-reported no prior antiretroviral (ARV) therapy use and were tested for viral load (n = 951; 27% of all participants), 136 (14%) had HIV-1 RNA less than 400 copies/ml. ARV drugs were detected in 52 (39%) of 134 participants tested. Adjusting for undisclosed ARV use increased the overall estimate of virally suppressed individuals on ARV therapy by 1.4% from 70.2 to 71.6%.
Conflict of interest statement
Author Disclosure Statement
All authors have declared that no competing interest exists.
Source: PubMed